Modafinil/Adrafinil (Research-Context): The Complete Supplement Guide

Quick Reference Card

Overview

The Basics

Modafinil is a prescription medication that promotes wakefulness. It was originally developed to treat narcolepsy, a condition where people experience uncontrollable daytime sleepiness, and it is also prescribed for shift work sleep disorder and obstructive sleep apnea. Over the past two decades, it has gained significant attention in the nootropics community as a "smart drug" that may improve focus, productivity, and mental clarity.

Adrafinil is a closely related compound that your body converts into modafinil through liver metabolism. Think of adrafinil as a slower-acting version of the same thing. The key difference is accessibility: modafinil requires a prescription in most countries, while adrafinil can be purchased without one in some markets, including the United States. This has made adrafinil popular among people who want modafinil-like effects without navigating the prescription process.

It is important to understand that these are pharmacologically active drugs, not traditional dietary supplements. Modafinil was developed by the French pharmaceutical company Lafon Laboratories in the 1970s and received FDA approval in 1998 for narcolepsy treatment. Adrafinil was first marketed in France in 1985 but was withdrawn from the French market in 2011 after regulators were unable to confirm that its benefits outweighed its risks.

The Science

Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) is classified as a eugeroic, or wakefulness-promoting agent, pharmacologically distinct from traditional psychostimulants such as amphetamines, methylphenidate, and cocaine [6]. It received FDA approval in 1998 (brand name Provigil) for the treatment of excessive daytime sleepiness associated with narcolepsy, later expanding to shift work sleep disorder and obstructive sleep apnea as adjunctive therapy [10].

Adrafinil (2-(diphenylmethyl)sulfinyl-N-hydroxyacetamide, CRL-40028) is a prodrug that undergoes hepatic metabolism to yield modafinil as its primary active metabolite and modafinilic acid as an inactive byproduct [8]. The conversion involves hydrolysis of the amide bond and reduction of the sulfoxide group. Adrafinil has a short half-life of approximately 1 hour, while its active metabolite modafinil has a considerably longer half-life of 12-15 hours, with the R-enantiomer persisting longer than the S-enantiomer [8].

Modafinil is classified as a Schedule IV controlled substance in the United States, acknowledging some potential for abuse and dependence, while adrafinil remains unscheduled and is available as an over-the-counter compound in the US market [8]. Both substances are listed as non-specified stimulants on the 2026 WADA Prohibited List, banned in-competition [12].

Chemical & Nutritional Identity

Mechanism of Action

The Basics

Modafinil and adrafinil promote wakefulness through a different pathway than traditional stimulants like Adderall or Ritalin. While those drugs work broadly across the brain to increase dopamine and norepinephrine, modafinil appears to be more targeted in its approach.

Think of your brain as having multiple "wake-up systems" that work together to keep you alert. Modafinil seems to gently activate several of these at once rather than hammering just one. It nudges your brain's dopamine system (involved in motivation and reward), your norepinephrine system (alertness and attention), your histamine system (wakefulness), and your orexin system (the master switch for sleep-wake cycles). At the same time, it appears to quiet the GABA system, which is your brain's primary "calm down" signal.

This multi-system approach may explain why modafinil feels different from traditional stimulants to most users: it promotes a more natural-feeling wakefulness without the jitteriness, euphoria, or crash that often accompanies amphetamine-type drugs.

The Science

Modafinil exhibits a complex, multi-target pharmacological profile that remains incompletely understood despite decades of research [1]. Its mechanism is distinct from traditional psychostimulants in several key respects:

Dopaminergic activity: Modafinil binds competitively to the dopamine transporter (DAT) with weak but selective affinity, inhibiting dopamine reuptake and increasing extracellular dopamine levels in the brain, including the nucleus accumbens [5][7]. Wake-promoting actions are absent in DAT-knockout mice, confirming the essential role of dopaminergic signaling [6]. Notably, modafinil's interaction with DAT is conformationally distinct from cocaine and amphetamine, potentially explaining its lower abuse liability [7].

Noradrenergic activity: Modafinil inhibits norepinephrine reuptake in noradrenergic nerve endings and activates central alpha-1 adrenergic receptors as an agonist [6][1].

Orexinergic/histaminergic activation: Modafinil activates orexin-producing neurons in the hypothalamus, which in turn stimulate histamine release in the anterior hypothalamus via the tuberomammillary nucleus. This orexin-histamine cascade is believed to be a primary driver of wakefulness. Histamine release requires intact orexinergic transmission, as demonstrated by the absence of modafinil-induced histamine release in orexin-knockout mice [6].

GABAergic/glutamatergic modulation: Modafinil decreases local GABA transmission while increasing excitatory glutamatergic signaling, shifting the excitation-inhibition balance toward wakefulness [6][1].

Serotonergic activity: Modafinil amplifies cortical serotonin release through electro-neurosecretory coupling mechanisms rather than reuptake inhibition [6].

Selective neuronal activation: Unlike amphetamine, which induces c-fos gene expression across the entire brain including the caudate, modafinil selectively and prominently induces c-fos expression in the hypothalamus, suggesting more targeted neuronal activation [6].

Absorption & Bioavailability

The Basics

If you take adrafinil, your liver needs to convert it into modafinil before it can work. This extra step means adrafinil takes longer to kick in (usually 1-2 hours to reach peak levels) and only about 50-80% of the dose reaches your bloodstream as active modafinil. Modafinil itself is absorbed more directly and predictably.

Modafinil can be taken with or without food. Food does not significantly block absorption, though it may slightly delay how quickly you feel the effects. The drug has a long duration of action, with effects lasting 12-15 hours for most people, which is why taking it early in the morning is strongly recommended to avoid sleep disruption.

One practical note: because adrafinil must be processed by the liver, roughly 3 mg of adrafinil produces effects equivalent to about 1 mg of modafinil. This is why adrafinil doses (300-600 mg) are considerably higher than modafinil doses (100-200 mg).

The Science

Adrafinil pharmacokinetics: Adrafinil exhibits a bioavailability of approximately 50-80% following oral administration, with peak plasma concentrations achieved within 1-2 hours. It undergoes extensive first-pass hepatic metabolism via two primary enzymatic reactions: hydrolysis of the amide bond and reduction of the sulfoxide group, yielding modafinil (active) and modafinilic acid (inactive) [8]. Adrafinil's own elimination half-life is approximately 1 hour, with 75% of metabolism occurring in the liver. Excretion is primarily renal via metabolites. The hepatic conversion step introduces both delay in onset and inter-individual variability in effective dose.

Modafinil pharmacokinetics: The R-enantiomer of modafinil has an apparent half-life of 12-15 hours, while the S-enantiomer has a shorter half-life of 4-5 hours [8]. Both enantiomers undergo extensive hepatic metabolism to form inactive metabolites prior to urinary elimination. Modafinil is a moderate inducer of CYP3A4 and a moderate inhibitor of CYP2C19, with clinically relevant effects on co-administered drugs metabolized by these pathways [10][11].

Research & Clinical Evidence

Wakefulness and Sleep Disorders

The Basics

This is where the evidence is strongest. Modafinil was specifically designed to treat excessive daytime sleepiness, and multiple large clinical trials have confirmed its effectiveness for narcolepsy, shift work sleep disorder, and obstructive sleep apnea. People with these conditions consistently report improved alertness and ability to function during their waking hours.

The Science

Modafinil's FDA approval is based on robust clinical trial data across three primary indications. A systematic review by Ballon & Feifel (2006) identified 33 double-blind, placebo-controlled trials demonstrating efficacy for sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea [3]. The StatPearls clinical review confirms FDA-approved indications: narcolepsy, shift work sleep disorder, and obstructive sleep apnea (as adjunct to CPAP) in adults [11].

Cognitive Enhancement in Healthy Adults

The Basics

Many people take modafinil hoping it will make them smarter or more productive. The reality is more nuanced. Research suggests modafinil provides a small but measurable boost to cognitive performance in non-sleep-deprived adults. The effects are real but modest -- do not expect the dramatic transformation depicted in movies like "Limitless." The benefits are most noticeable for tasks requiring sustained attention and focus rather than creative thinking or complex problem-solving.

The Science

A meta-analysis of 19 placebo-controlled trials (Kredlow et al., 2019) examined single-dose modafinil effects on cognitive functioning in non-sleep-deprived adults across attention, executive functioning, memory, and processing speed domains. The overall positive effect of modafinil over placebo was small but statistically significant (g = 0.10; 95% CI: 0.05-0.15; P < 0.001). No significant differences between cognitive domains were found. Notably, no significant moderation was found for modafinil dose (100 mg vs 200 mg) or for population type (psychiatric vs nonpsychiatric) [2]. The authors concluded: "The available evidence indicates only limited potential for modafinil to act as a cognitive enhancer outside sleep-deprived populations."

An earlier comprehensive review (Minzenberg & Carter, 2008) noted that modafinil improves function in working memory, episodic memory, and other processes dependent on prefrontal cortex and cognitive control, with effects observed in rodents, healthy adults, and across several psychiatric disorders [1].

Off-Label Psychiatric Applications

The Basics

Researchers have explored modafinil for conditions beyond sleep disorders, including ADHD, treatment-resistant depression, and cognitive dysfunction in schizophrenia. Results have been mixed: some people with these conditions report meaningful benefits, but the evidence is not strong enough for official recommendations.

The Science

ADHD: Several RCTs have evaluated modafinil for ADHD. Biederman et al. (2005) demonstrated efficacy and safety in children and adolescents in a randomized, double-blind, flexible-dose study. Arnold et al. (2014) conducted a 9-week dose-finding study in adults with ADHD. Results were positive but modafinil did not receive FDA approval for ADHD due to concerns about Stevens-Johnson Syndrome risk in pediatric populations [11].

Depression augmentation: A systematic review and meta-analysis of RCTs (Goss et al., 2013) found that modafinil augmentation showed benefit in unipolar and bipolar depression [4].

Cocaine dependence: Kampman et al. (2015) conducted a double-blind, placebo-controlled trial for cocaine dependence treatment, with modestly positive results [11].

Adrafinil-Specific Clinical Evidence

The Basics

The evidence specifically for adrafinil (as opposed to modafinil) is quite limited. Most of the rigorous clinical research has been conducted on modafinil directly. The handful of adrafinil studies are decades old, conducted in France in the 1980s and 1990s, primarily in elderly patients with cognitive complaints.

The Science

Adrafinil-specific human clinical data is limited to early French studies from the 1970s-1990s. Six studies described by Milgram et al. (1999) enrolled ambulatory and hospitalized patients aged 45 and older (majority over 65) with "problems in focusing attention, sleep, memory, and mild depression." Results indicated improvements in vigilance, attention, memory, orientation, depression, fatigue, autonomy, and sociability. However, these studies had significant methodological limitations including unreported study details, limiting generalizability [8].

A French marketing authorization committee reviewed the clinical evidence in 2011 and was unable to conclude that adrafinil provided benefit sufficient to outweigh its known adverse effects, resulting in market withdrawal [8].

Evidence & Effectiveness Matrix

Categories Not Scored: Fat Loss, Muscle Growth, Weight Management, Food Noise, Libido, Sexual Function, Joint Health, Inflammation, Pain Management, Recovery & Healing, Gut Health, Digestive Comfort, Nausea & GI Tolerance, Skin Health, Hair Health, Heart Health, Blood Pressure, Heart Rate & Palpitations, Hormonal Symptoms, Temperature Regulation, Fluid Retention, Body Image, Immune Function, Bone Health, Longevity & Neuroprotection, Cravings & Impulse Control, Stress Tolerance

Benefits & Potential Effects

The Basics

The primary benefit of modafinil/adrafinil is wakefulness promotion. If you are excessively sleepy due to a medical condition, shift work, or sleep deprivation, these compounds can meaningfully improve your ability to stay alert and function.

Beyond wakefulness, many users report improvements in:

• Focus and concentration -- being able to sustain attention on tasks for longer periods
• Productivity -- getting more done, reduced procrastination
• Mental clarity -- reduction in "brain fog," sharper thinking
• Mood -- some users experience improved mood and reduced depressive symptoms

These effects are most pronounced in people who are sleep-deprived or have underlying conditions that impair alertness. Healthy, well-rested individuals tend to experience more modest benefits.

The Science

FDA-approved benefits: Reduction of excessive daytime sleepiness in narcolepsy, shift work sleep disorder, and obstructive sleep apnea (adjunctive to CPAP) [10][11].

Cognitive benefits: Modafinil improves multiple cognitive domains including working memory, episodic memory, attention, and processing speed, with effects observed across psychiatric and non-psychiatric populations. However, the magnitude of cognitive enhancement in non-sleep-deprived populations is small (g = 0.10) [2]. More substantial cognitive benefits have been demonstrated in sleep-deprived individuals and those with cognitive impairment secondary to psychiatric conditions [1].

Fatigue management: Evidence supports efficacy in cancer-related fatigue, multiple sclerosis fatigue, and depression-associated fatigue [6].

Military applications: Comparative studies in sleep-deprived military personnel demonstrate modafinil 400 mg provides 11.5 hours of alertness enhancement with fewer subjective side effects than dextroamphetamine 20 mg (13.5 hours) or caffeine 600 mg (5.5 hours) [6].

Managing a thoughtful supplement protocol shouldn't require a degree in nutrition science. The app handles the complexity so you can focus on staying consistent.

When your stack includes several supplements, each with its own dose, form, and timing requirements, the logistics alone can derail consistency. Doserly consolidates all of it into one protocol view, so every dose across your entire routine is accounted for without spreadsheets or guesswork.

Side Effects & Safety Considerations

The Basics

Modafinil is generally considered well-tolerated compared to traditional stimulants, but it is not without risks. The most common side effects include headache, nausea, anxiety, insomnia, and dizziness. Many of these are dose-dependent and may improve with time or dose adjustment.

The most important safety concern is the rare but potentially life-threatening risk of severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). If you develop any kind of rash while taking modafinil, stop immediately and seek medical attention.

Adrafinil carries an additional concern: because it must be processed by the liver, prolonged use may stress liver function. Periodic liver function testing is recommended for anyone using adrafinil regularly.

The Science

Common adverse effects (modafinil): Headache (34%), nausea (11%), anxiety/nervousness, insomnia, dizziness, back pain, diarrhea, rhinitis, indigestion [10].

Serious adverse effects:

• Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN): Rare but potentially fatal severe skin reactions. Risk was a factor in FDA's decision not to approve modafinil for pediatric ADHD.
• DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): Multi-organ hypersensitivity reaction affecting liver, kidneys, and heart.
• Psychiatric symptoms: Depression, anxiety, hallucinations, suicidal ideation, mania. Higher risk in patients with history of psychiatric disorders [10].
• Cardiovascular effects: Increased resting heart rate and blood pressure; sympathomedullary activation. Use restricted in patients with heart disease, mitral valve prolapse, or left ventricular hypertrophy [6].

Adrafinil-specific safety concerns:

• Hepatic stress from first-pass metabolism; elevated liver enzymes reported in some users. Periodic monitoring of ALT/AST recommended [8].
• Case report of irreversible orofacial dyskinesia after 10 months of 900 mg daily [8].
• Case report of treatment-resistant hypertension on 900 mg daily [8].

Dependence potential: Modafinil is classified as Schedule IV, acknowledging low but present abuse potential. Volkow et al. (2009) demonstrated that modafinil blocks DAT and increases dopamine in the nucleus accumbens, a mechanism shared with addictive drugs. However, clinical reports of dependence remain rare compared to other psychostimulants [6].

Contraceptive interaction: Modafinil induces CYP3A4 and may decrease the effectiveness of hormonal contraceptives. Alternative non-hormonal birth control should be used during treatment and for one month after discontinuation [10].

Managing side effect risks across a multi-supplement stack can feel overwhelming, especially when interactions between supplements, medications, and foods add layers of complexity. Doserly brings all of that into a single safety view so nothing falls through the cracks.

Rather than researching every possible interaction yourself, the app checks your full stack automatically and flags supplement-drug and supplement-supplement interactions that warrant attention.

Dosing & Usage Protocols

The Basics

Modafinil (prescription):

• Typical starting dose: 100 mg once daily in the morning
• Standard dose: 200 mg once daily
• For shift work: take 1 hour before the start of your shift
• Lower doses (50-100 mg) may be sufficient for some people
• Elderly patients or those with liver impairment may need reduced doses

Adrafinil (unregulated):

• Commonly used range: 300-600 mg per day
• Rough conversion: 3 mg adrafinil produces approximately 1 mg modafinil equivalent
• Take on an empty stomach for faster absorption
• Take early in the morning to minimize sleep disruption
• Community recommends cycling (not daily use) due to liver concerns and tolerance

Adrafinil dosing information is derived from community reports and limited clinical data. There are no FDA-established dosing guidelines for adrafinil. Consult a healthcare provider before use.

The Science

Modafinil clinical dosing: Standard FDA-approved dosing is 200 mg once daily for narcolepsy and obstructive sleep apnea, taken in the morning. For shift work sleep disorder, 200 mg is taken approximately 1 hour before the shift begins [10]. Dose adjustment downward is recommended for hepatic impairment and elderly patients. Clinical trials have evaluated doses ranging from 100-400 mg, with 200 mg considered the optimal balance of efficacy and tolerability [11].

Adrafinil dosing: No standardized clinical dosing exists. French clinical studies used 900 mg daily for elderly populations [8]. Community sources commonly cite 300-600 mg as the effective range, which is notably lower than the 900 mg clinical dose. The higher clinical dose was associated with all three published case reports of serious adverse effects (orofacial dyskinesia, uncontrolled hypertension, interaction symptoms), while the lower community-preferred doses lack formal clinical validation.

There is a significant gap between clinically studied adrafinil doses (900 mg/day) and community-preferred doses (300-600 mg/day). Neither range has been rigorously validated for the off-label cognitive enhancement purposes that drive most current use. Consult a healthcare professional before using adrafinil at any dose.

What to Expect (Timeline)

First dose (Day 1):

• Modafinil: effects typically noticeable within 30-60 minutes. Adrafinil: 1-2 hours.
• Increased alertness, reduced sleepiness, possibly improved focus
• Some users experience headache, especially if combined with caffeine
• May notice reduced appetite
• Sleep may be disrupted if taken too late in the day

First week (Days 1-7):

• Most common side effects (headache, nausea) tend to occur early and diminish
• Focus and productivity benefits become more apparent
• Sleep disruption may be the most noticeable negative effect
• Some users report "not noticing" the drug, then realizing they've been more productive than usual

Weeks 2-4:

• Benefits stabilize for most users
• Body adjusts to common side effects
• Some users begin noticing tolerance if taking daily
• Optimal personal dose usually identified during this period

Months 1-3:

• Tolerance may become apparent with daily use
• Many experienced users switch to intermittent/as-needed dosing
• Long-term effects on mood become more noticeable (positive or negative)
• For adrafinil users: consider liver function monitoring at this point

3+ months:

• Users who take modafinil daily for medical conditions (narcolepsy) report sustained benefit, though some require dose adjustment over time
• Intermittent users generally report more consistent effects than daily users
• Community strongly recommends periodic breaks to prevent tolerance

One of the hardest parts of any supplement routine is knowing whether it's working when results unfold gradually over weeks or months. Doserly gives you a visual timeline of your entire supplementation history mapped against the outcomes you care about.

When everything is in one view, you can compare how different supplements in your stack are performing over the same period.

Interactions & Compatibility

Synergistic

• Caffeine -- commonly combined for enhanced wakefulness, though potentiation of side effects (headache, anxiety) is frequently reported; start with reduced caffeine doses
• L-Theanine -- frequently paired to reduce jitteriness and anxiety associated with modafinil/caffeine combinations

Caution / Avoid

Drug Interactions (Contraindicated or Serious):

• MAOIs (phenelzine, selegiline, tranylcypromine) -- taking modafinil with MAOIs has led to serious adverse effects including hypertensive crisis
• Hormonal contraceptives -- modafinil induces CYP3A4 and reduces effectiveness of birth control pills, patches, rings, implants, injections, and IUDs. Use alternative non-hormonal contraception during and for 1 month after treatment [10]

Drug Interactions (Moderate):

• Warfarin (Coumadin) -- may alter warfarin effects; INR monitoring recommended [10]
• Cyclosporine -- reduced cyclosporine levels possible
• Diazepam (Valium) -- modafinil may inhibit CYP2C19-mediated metabolism
• Phenytoin (Dilantin) -- altered phenytoin levels possible
• Omeprazole (Prilosec) -- interaction via CYP2C19 pathway [10]
• Antihypertensive drugs -- adrafinil/modafinil may increase blood pressure, potentially reducing antihypertensive efficacy

CYP Enzyme Effects

• CYP3A4 inducer (moderate): May decrease levels of CYP3A4 substrates
• CYP2C19 inhibitor: May increase levels of CYP2C19 substrates
• Interactions with CYP1A2, CYP2B6, CYP2C9 substrates also reported

Food & Beverage Interactions

• Grapefruit/grapefruit juice -- potential CYP3A4 interaction; discuss with doctor [10]
• Alcohol -- avoid; may increase dizziness and impair judgment [10]
• Caffeine -- community reports significant potentiation of both positive and negative effects. Headaches and anxiety commonly amplified

Supplement Interactions

Cross-links will be expanded as more supplement guides are published.

How to Take / Administration Guide

• Timing: Take modafinil in the morning (for narcolepsy/OSA) or 1 hour before shift (for SWSD). Adrafinil should be taken in the morning or early afternoon. Never take either compound in the evening.
• With food: Modafinil can be taken with or without food. Adrafinil may absorb faster on an empty stomach.
• Hydration: Maintain adequate hydration throughout the day. Dehydration is a commonly reported issue.
• Caffeine: Start with reduced caffeine intake when beginning modafinil/adrafinil. The combination frequently causes headaches and increased anxiety.
• Splitting doses: Standard modafinil dosing is once daily. Some users split the dose (e.g., 100 mg morning + 100 mg noon) but this increases insomnia risk.
• Cycling (adrafinil): Due to liver metabolism concerns, community recommends not taking adrafinil daily. Common approaches include 3-4 days on, 3-4 days off, or as-needed use only.
• Do not stop abruptly without consulting your doctor if taking prescription modafinil [10].
• Do not share modafinil with others. Selling or giving away modafinil is illegal [10].

Choosing a Quality Product

Modafinil (prescription): Available only via prescription in most countries. Generic versions are widely available. Brand names include Provigil (US), Alertec (Canada), and Modavigil. Ensure your pharmacy dispenses from a reputable manufacturer.

Adrafinil (unregulated): This is where quality concerns are most significant. Because adrafinil is sold as an unregulated compound, there is no FDA oversight of purity, potency, or manufacturing standards. When sourcing adrafinil:

• Demand third-party testing: Look for vendors that provide Certificates of Analysis (CoA) from independent laboratories confirming identity, purity, and absence of contaminants.
• Avoid proprietary blends: Know exactly what dose of adrafinil you are getting.
• Form matters: Adrafinil is available as powder or capsules. Pre-measured capsules reduce dosing error but may cost more.
• Purity concerns: The unregulated nature of adrafinil means batch-to-batch consistency is not guaranteed. Low-quality products may contain degradation products, incorrect doses, or contaminants.
• No USP/NSF certification exists for adrafinil, as it is not classified as a dietary supplement by these organizations.

Because adrafinil is unregulated in the US, there are no GMP requirements for its manufacture. Product quality varies significantly between vendors. Independent testing has not been conducted at scale for adrafinil products.

Storage & Handling

• Temperature: Store at room temperature, 68-77 F (20-25 C) [10]
• Moisture: Keep in a tightly closed container, away from excess moisture. Do not store in the bathroom.
• Light: No specific light sensitivity noted, but store away from direct sunlight as general best practice.
• Security: Modafinil is a controlled substance. Store in a safe place where no one else can access it. Keep track of how many tablets remain [10].
• Disposal: Do not flush. Use a medicine take-back program or follow FDA disposal guidelines [10].
• Shelf life: Follow the expiration date on the prescription label. Adrafinil powder should be stored in an airtight container; degradation may accelerate with moisture exposure.

Lifestyle & Supporting Factors

Modafinil/adrafinil should never be used as a substitute for adequate sleep. The most important lifestyle factor for anyone considering these compounds is establishing good sleep hygiene:

• Sleep first: Aim for 7-9 hours of quality sleep. Modafinil treats sleepiness symptoms but does not replace the restorative functions of sleep.
• Exercise: Regular physical activity improves cognitive function and sleep quality. Community reports suggest exercise in the morning while on modafinil can help prevent evening insomnia.
• Nutrition: Maintain regular meals. Modafinil may suppress appetite, so be mindful of adequate caloric intake.
• Hydration: Drink at least 2 liters of water daily. Dehydration is a commonly reported contributor to headaches.
• Stress management: Modafinil does not address the root causes of fatigue from chronic stress, overwork, or burnout. Address these factors directly.
• Medical monitoring: For prescription modafinil, maintain regular follow-ups. For adrafinil, consider periodic liver function testing (ALT, AST).
• Biomarker tracking: If using modafinil/adrafinil for productivity or cognitive enhancement, track your outcomes over time to determine whether the benefits persist and justify continued use.

Regulatory Status & Standards

United States

• Modafinil: Schedule IV controlled substance. FDA-approved for narcolepsy, shift work sleep disorder, and obstructive sleep apnea. Prescription required. Generic versions widely available.
• Adrafinil: Not FDA-approved for any indication. Not scheduled by the DEA. Available for purchase as an unregulated compound. Not classified as a dietary supplement under DSHEA.

International

• France: Adrafinil was first marketed in 1985 (brand name Olmifon). Withdrawn from market in 2011 after benefit-risk reassessment [8].
• United Kingdom: Both modafinil and adrafinil are prescription-only medications.
• Australia: Modafinil is Schedule 4 (prescription only). Adrafinil is similarly classified.
• Canada: Modafinil is available by prescription (brand name Alertec). Adrafinil is not regulated under the Controlled Drugs and Substances Act but is not approved for sale by Health Canada.
• Germany: Both require a prescription.

Athlete / Anti-Doping Status

Both modafinil and adrafinil are prohibited in-competition by WADA and all affiliated national anti-doping organizations.

• WADA 2026 Prohibited List: Both modafinil and adrafinil are explicitly listed as non-specified stimulants under S6.A, prohibited in-competition [12].
• New for 2026: Fladrafinil and flmodafinil (potent analogs sold as supplements) were added to the S6.A list as non-specified stimulants [13].
• Hydrafinil (fluorenol): Also listed as a non-specified stimulant.
• TUE required: Athletes with legitimate medical need (narcolepsy) must apply for a Therapeutic Use Exemption.
• No certified-for-sport programs exist for adrafinil, as it is not a recognized dietary supplement.
• GlobalDRO status: Both substances will show as prohibited in-competition across all countries in the GlobalDRO database.
• NCAA: Modafinil is on the NCAA banned stimulant list. Student-athletes should be aware that adrafinil, as a prodrug of modafinil, would produce the same positive test result.
• Recent WADA enforcement (March 2026): WADA imposed an Analytical Testing Restriction on the Polish Anti-Doping Laboratory specifically for modafinil-related substances, reflecting ongoing scrutiny of testing procedures for these compounds [12].

Frequently Asked Questions

Is adrafinil the same as modafinil?
Not exactly. Adrafinil is a prodrug that your liver converts into modafinil. They produce similar effects, but adrafinil has a slower onset, is less potent milligram-for-milligram, and places additional metabolic burden on the liver. Modafinil is available only by prescription; adrafinil can be purchased without one in some countries.

Can I take modafinil every day?
Many people with narcolepsy and other sleep disorders take modafinil daily under medical supervision for years. However, for off-label use as a cognitive enhancer, many users report diminishing effects with daily use and recommend intermittent or as-needed dosing to minimize tolerance development.

Will modafinil show up on a drug test?
Standard workplace drug tests (5-panel, 10-panel) do not test for modafinil. However, specialized tests can detect modafinil and its metabolites. It will always show up on anti-doping tests (WADA, USADA, NCAA).

Is adrafinil safe for long-term use?
This is uncertain. Adrafinil was withdrawn from the French market in 2011 due to insufficient evidence of benefit relative to risk. The liver conversion step raises concerns about hepatic stress with prolonged use. If you use adrafinil regularly, periodic liver function monitoring is strongly advised.

How does modafinil compare to Adderall?
Modafinil and Adderall work through different mechanisms. Modafinil is a wakefulness-promoting agent with a more targeted neural profile and generally milder side effects. Adderall is an amphetamine-based stimulant with stronger effects on focus and ADHD symptoms but also more pronounced side effects (appetite suppression, cardiovascular stimulation, higher abuse potential). Community consensus is that modafinil is better for wakefulness and mild focus enhancement, while Adderall is more effective for ADHD symptom management.

Can I drink coffee while taking modafinil?
Yes, but with caution. Many users report that caffeine significantly amplifies both the positive and negative effects of modafinil, particularly headaches and anxiety. Start with reduced caffeine intake and adjust based on your response.

Myth vs. Fact

Myth: Modafinil is a "Limitless pill" that dramatically boosts intelligence.
Fact: A meta-analysis of 19 clinical trials found that modafinil produces only a small cognitive enhancement effect (g = 0.10) in non-sleep-deprived adults [2]. While users report improved focus and productivity, the effect is modest and most pronounced in sleep-deprived or cognitively impaired populations.

Myth: Modafinil has no addiction potential because it is different from amphetamines.
Fact: While modafinil has lower abuse liability than amphetamines, it is classified as Schedule IV precisely because it has some dependence potential. It blocks the dopamine transporter and increases dopamine in the nucleus accumbens, a mechanism shared with addictive drugs [5][6]. Clinical dependence cases are rare but have been reported.

Myth: Adrafinil is a safe, natural alternative to prescription modafinil.
Fact: Adrafinil is fully synthetic, not natural. It was withdrawn from the French market in 2011 after regulators could not confirm sufficient benefit. Because it requires liver conversion, it may pose additional hepatotoxicity risks compared to modafinil. Its unregulated status means product quality is not guaranteed [8].

Myth: You can take modafinil indefinitely without tolerance.
Fact: While some narcolepsy patients maintain benefit for years, many users, particularly those using it off-label for cognitive enhancement, report diminishing effects with daily use. Community experience consistently supports cycling or intermittent use to maintain effectiveness.

Myth: Modafinil is completely safe with no serious side effects.
Fact: While generally well-tolerated, modafinil carries risks of rare but serious adverse reactions including Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, DRESS, and psychiatric symptoms. It also interacts with numerous medications including hormonal contraceptives [10].

Sources & References

Clinical Reviews and Meta-Analyses

[1] Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477-1502. PMID: 17712350.

[2] Kredlow MA, Keshishian A, Oppenheimer S, Otto MW. The Efficacy of Modafinil as a Cognitive Enhancer: A Meta-Analytic Review. J Clin Psychopharmacol. 2019;39(5):455-461.

[3] Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67(4):554-566. PMID: 16669720.

[4] Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101-7.

Primary Research Articles

[5] Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148-1154.

[6] Kim D. Practical Use and Risk of Modafinil, a Novel Waking Drug. Environ Health Toxicol. 2012;27:e2012007. PMC3286657.

[7] Wisor JP. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;4:139. PMID: 24109471.

Adrafinil-Specific

[8] Lowe DW, Dobson E, Jewett AG, Whisler EE. Adrafinil: Psychostimulant and purported nootropic? Am J Psych Res J. 2021;17(1):7-9.

[9] Milgram NW, Callahan H, Siwak C. Adrafinil: a novel vigilance promoting agent. CNS Drug Rev. 1999;5:193-212.

Government / Institutional Sources

[10] MedlinePlus Drug Information: Modafinil. U.S. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a602016.html. Accessed 2026-03-25.

[11] Greenblatt K, Adams N. Modafinil. StatPearls/NCBI Bookshelf. PMID: 30285371. Updated clinical reference.

Regulatory Sources

[12] World Anti-Doping Agency. 2026 Prohibited List International Standard. Effective January 1, 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

[13] WADA. Summary of Major Modifications and Explanatory Notes: 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026_list_explanatory_note_en_final_september_2025.pdf

Related Supplement Guides

Same Category

• Piracetam — racetam-class nootropic, sometimes stacked

Common Stacks

• Caffeine — commonly stacked with modafinil; interaction considerations
• L-Theanine — frequently combined for focus without jitteriness

Related Health Goal

• Bacopa Monnieri — nootropic with complementary cognitive mechanisms
• Rhodiola Rosea — adaptogen commonly discussed as modafinil alternative
• Lion's Mane — nootropic mushroom for long-term cognitive support